Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, ...

Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an ...

The pharma giant will lose its patent protection on semaglutide, which is sold as Ozempic and Wegovy, in Canada after not ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...

Novo Nordisk has taken initiatives to accelerate target discovery by implementing AI/ML technologies into genetic and ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...